Core Viewpoint - The company plans to issue 69.256 million shares, representing approximately 6.98% of its total issued shares, to raise funds for clinical trials and operational needs [1] Fundraising Details - The placement price is set at HKD 12.18 per share, which is about 4.0% lower than the closing price of HKD 12.69 on February 2 [1] - The total expected proceeds from the placement are approximately HKD 843.5 million, with a net amount of about HKD 835.3 million after expenses [1] Allocation of Proceeds - Approximately 90% of the net proceeds is intended for the preparation, groundwork, and initiation of global Phase III clinical trials for the obesity treatment small molecule oral GLP-1 receptor agonist ASC30 [1] - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [1]

来源：格隆汇APP 配售股份总数占公司于本公告日期已发行股份数目(即约9.919亿股股份，不包括708.421万股库存股份) 约6.98%。每股配售股份的配售价12.18港元较2月2日(即最后交易日)于联交所所报的收市价每股股份 12.69港元折让约4.0%。 配售所得款项总额预期合共约为8.435亿港元，而配售所得款项净额预期合共约为8.353亿港元。配售事 项所得款项净额中约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试 验的准备、基础工作及启动，而配售事项所得款项净额中约10%建议用作营运资金及其他一般公司用 途。 格隆汇2月3日丨歌礼制药-B(01672.HK)发布公告，2026年2月3日(交易时段前)，公司与配售代理(即花 旗)订立配售协议，据此，配售代理同意作为公司代理，按尽力基准促使合共不少于六名承配人按每股 股份12.18港元的配售价购买6925.6万股配售股份，惟须遵守配售协议所载条款及条件。预期概无承配人 将于紧随配售完成后成为公司的主要股东。 ...

Core Viewpoint - The company, Gilead Sciences-B (01672), plans to issue 69.256 million shares, representing approximately 6.98% of its total issued shares as of the announcement date, to raise funds for clinical trials and operational needs [1] Group 1: Share Placement Details - The placement price is set at HKD 12.18 per share, which is about a 4.0% discount compared to the closing price of HKD 12.69 on February 2 [1] - The total expected proceeds from the placement are approximately HKD 843.5 million, with net proceeds estimated at around HKD 835.3 million [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds is intended for the preparation, groundwork, and initiation of global Phase III clinical trials for the oral GLP-1 receptor agonist ASC30, aimed at treating obesity [1] - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告概不得直接或間接於美國境內或向美國境內派發。本公告並不構成亦 不組成在美國購買或認購證券的任何要約或招攬的一部分。本公告所述之本公司股份尚未且將 不會根據證券法登記，且除根據證券法登記規定獲豁免外，不得在美國提呈發售或出售。本公 告所述之本公司股份將(i)僅根據證券法第144A條獲豁免登記向合資格機構買家，及(ii)根據證 券法S規例於美國境外進行之離岸交易中提呈發售及出售。本公司無意於美國公開發售本公司 股份。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 根據一般授權配售新股份 獨家整體協調人及獨家配售代理 董事會欣然宣佈，於二零二六年二月三日（交易時段前），本公司與配售代理訂 立配售協議，據此，本公司同意委任配售代理，而配售 ...

Market Performance - The Hong Kong stock market opened lower on January 30, with the Hang Seng Index dropping by 496.82 points, a decline of 1.78%, closing at 27,471.27 points [1] - The Hang Seng Tech Index fell by 104.83 points, down 1.79%, to 5,736.27 points, while the National Enterprises Index decreased by 2.08% to 9,354.3 points [1] - Major tech stocks experienced declines, with Alibaba down 2.71%, Tencent down 1.53%, and JD Group down 1.4% [1] Company Earnings Forecasts - Guoquan (02517.HK) expects revenue for 2025 to be approximately 7.75 billion to 7.85 billion yuan, a year-on-year increase of about 19.8% to 21.3%, with net profit projected at 443 million to 463 million yuan, up 83.7% to 92.0% [2] - Sunny Optical Technology (02382.HK) anticipates a net profit of 4.5886 billion to 4.7235 billion yuan for 2025, representing a year-on-year increase of approximately 70.0% to 75.0% [3] - Baidu (02315.HK) forecasts revenue of 1.369 billion to 1.389 billion yuan for 2025, with a net profit of 162 million to 182 million yuan, reflecting a significant increase of 384.26% to 443.88% [3] - Spring Medical (01858.HK) expects a net profit of 245 million to 288 million yuan for 2025, an increase of 96.01% to 130.41% [4] - Encounter Small Noodles (02408.HK) projects a net profit between 100 million to 115 million yuan for 2025, an increase of approximately 64.7% to 89.5% [5] - Macro Credit Development (09930.HK) issued a profit warning, expecting a decline in shareholder profit by 70% to 90% for 2025 [6] - Financial Street Securities (01476.HK) issued a profit alert, expecting a shareholder profit increase to approximately 327 million yuan for 2025 [7] Industry Insights - China Railway (00390.HK) recently won several major engineering contracts with a total bid amount of approximately 43.292 billion yuan [8] - New天绿色能源 (00956.HK) reported a cumulative power generation of 15.2104 million MWh for 2025, a year-on-year increase of 7.71% [9] - Huayi Pharmaceutical (01276.HK) received acceptance for a new indication application for its innovative drug, which may become a new treatment option for patients with unresectable liver cancer [9] - Citic Securities suggests focusing on three main lines in the short term: biomanufacturing, embodied intelligence, and 6G technology [11] - Guoyuan International believes that the Hong Kong stock market may continue to outperform the US market due to factors such as fiscal cliffs and geopolitical issues, benefiting from the low long-term valuation levels [12]

公司于2025年6月4日的公告中宣布地尼法司他(ASC40)在480例患者中开展的治疗中重度寻常性痤疮的 随机、双盲、安慰剂对照的III期临床研究(NCT06192264)达到所有主要、关键次要和次要终点。 歌礼制药-B(01672)发布公告，同类首创(first-in-class)、每日一次口服小分子脂肪酸合成酶(FASN)抑制剂 地尼法司他(ASC40)在中重度寻常性痤疮患者中的III期开放标签研究(NCT06248008)取得积极顶线结 果。 于近期完成的该第二项III期研究是一项在中国开展的开放标签的多中心研究，旨在评估地尼法司他 (ASC40)在240例中重度寻常性痤疮患者中的长期安全性。这240例患者均接受了40周的每日一次地尼法 司他(ASC40)治疗，且此前均接受过12周的地尼法司他(ASC40)或安慰剂治疗。主要终点包括治疗期间 发生的不良事件(treatment-emergent adverse event，TEAE)的发生率;严重不良事件(SAE)的发生率;及因不 良事件(AE)导致停药的发生率。地尼法司他(ASC40)显示出良好的安全性和耐受性特征。大部分治疗期 间发生的不良事件为轻度 ...

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced positive topline results from a Phase III open-label study of its first-in-class oral small molecule fatty acid synthase (FASN) inhibitor, denifasertib (ASC40), in patients with moderate to severe acne vulgaris [1] Group 1: Study Overview - The Phase III study was conducted in China and involved 240 patients with moderate to severe acne vulgaris [1] - The study aimed to evaluate the long-term safety of denifasertib (ASC40) over a 40-week treatment period, following a 12-week treatment with either denifasertib (ASC40) or placebo [1] Group 2: Safety and Tolerability - Key endpoints included the incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and the rate of discontinuation due to adverse events (AEs) [1] - Denifasertib (ASC40) demonstrated good safety and tolerability, with most adverse events being mild (Grade 1) or moderate (Grade 2) [1] - No Grade 3 or 4 adverse events or serious adverse events related to denifasertib (ASC40) were reported, and there were no reported deaths [1]

Core Insights - The company has announced positive topline results from a Phase III open-label study of its first-in-class oral small molecule FASN inhibitor, ASC40, for moderate to severe acne patients [1] - ASC40 demonstrated good safety and tolerability, with most adverse events being mild to moderate, and no severe adverse events reported [1] - The company has also achieved all primary and key secondary endpoints in a randomized, double-blind, placebo-controlled Phase III clinical study involving 480 patients [2] Group 1 - ASC40 was evaluated in a Phase III open-label study involving 240 moderate to severe acne patients, focusing on long-term safety [1] - The primary endpoints included the incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and the rate of discontinuation due to adverse events [1] - The study showed that there were no grade 3 or 4 adverse events related to ASC40, and no deaths were reported [1] Group 2 - The mechanism of action for ASC40 involves inhibiting de novo lipogenesis (DNL) in human sebocytes, directly reducing sebum production and inflammation [2] - Excessive sebum production is a major cause of acne, and ASC40's unique mechanism sets it apart from other acne treatments that do not address the root cause [2] - The company has obtained exclusive rights for ASC40 in Greater China from Sagimet Biosciences Inc. [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈，同類首創(first-in-class)、每日一次口服 小分子脂肪酸合成酶(FASN)抑制劑地尼法司他(ASC40)在中重度尋常性痤瘡患者 中的III期開放標籤研究(NCT06248008)取得積極頂線結果。 於近期完成的該第二項III期研究是一項在中國開展的開放標籤的多中心研究， 旨在評估地尼法司他(ASC40)在240例中重度尋常性痤瘡患者中的長期安全性。 這240例患者均接受了40周的每日一次地尼法司他(ASC40)治療，且此前均接受 過12周的地尼法司他(ASC40)或安慰劑治療。主要終點包括：(1)治療期間發生的 不良事件（treatment-emergent adverse event，TEAE）的發生率； ...

每经AI快讯，歌礼制药-B(01672.HK)午后涨超4%，截至发稿，涨3.85%，报13.76港元，成交额1218.55 万港元。 （文章来源：每日经济新闻） ...